SEC Form 4 · accession 0001179110-17-000677
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J Warmuth
Officer — Executive Vice President
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 5:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par valueF1 | Jan 4, 2017 | A | 15 | — | A | 42,874 | D | |
| Common shares without par valueF2 | holding | — | — | — | 39,413 | I | By trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 commonshares of Abbott.
- F2Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.